Newer compounds impacting on current MS DMDs

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Newer compounds impacting on current MS DMDs

Postby MSUK » Mon Nov 07, 2011 8:44 am

Newer compounds impacting on current MS disease modifying drugs


While Biogen Idec's Avonex and Teva's Copaxone continue to capture the majority of multiple sclerosis (MS) patients first starting on a disease-modifying agent (DMA), the introduction of Novartis' Gilenya, the only oral DMA currently on the market, appears to have impacted the average length of the time that patients remain on their first-line therapy before a switch may be initiated.

Gilenya, typically prescribed as a second or later-line DMA, has also negatively impacted the overall market share of certain DMAs compared to the 2010 audit fielded prior to the Gilenya launch, with Pfizer / EMD Serono's Rebif and Biogen Idec's Avonex, taking the greatest hit.... Read More - ... pageid/683
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service